Description:
Kalorama Information has closely observed the evolution of the cancer treatment market over the past two decades, evaluating the significant impact of new technologies. The Worldwide Market for Targeted Cancer Therapeutics delves into the burgeoning field of targeted therapies, highlighting current products and some of the most promising advancements on the horizon. This report covers targeted cancer therapies that achieve the following:
- Inhibit or deactivate chemical signals that promote cancer cell growth and division
- Modify proteins within cancer cells to induce cell death
- Prevent the formation of new blood vessels that supply cancer cells
- Activate the immune system to eliminate cancer cells
- Deliver toxins specifically to cancer cells while sparing normal cells
Report Highlights:
- Comprehensive Market Analysis:
- Insightful market data and projections for 2010-2025 across key segments:
- Global Targeted Cancer Therapeutic Market Size and Forecast (monoclonal antibodies, tyrosine kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CDK inhibitors, others)
- Cancer Monoclonal Antibody Market (2018-2025)
- Top 10 Cancer Indicated Monoclonal Antibodies (2017 and 2018 Sales)
- Monoclonal Antibodies in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Tyrosine Kinase Inhibitor Market (2018-2025)
- Top 10 Cancer Indicated Tyrosine Kinase Inhibitors (2017 and 2018 Sales)
- Tyrosine Kinase Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Angiogenesis Inhibitor Market (2018-2025)
- Angiogenesis Inhibitors in Cancer Therapy (Trade Name, Biological Name, Indication[s])
- CDK Inhibitor Market (2018-2025)
- CDK Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Proteasome Inhibitor Market (2018-2025)
- Proteasome Inhibitors in Cancer Therapy (Trade Name, Biological Name, Target, Indication[s])
- Other Targeted Therapies Market (2018-2025)
- Other Targeted Cancer Therapies (Classification, Trade Name, Biological Name, Target, Indication[s])
- Insightful market data and projections for 2010-2025 across key segments:
- Detailed Segment Insights:
- Extensive analysis of the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) markets, focusing on type and target:
- Cancer Monoclonal Antibody Market by Type and Target
- Development of the mAb Cancer Treatment Market (2010-2025)
- Monoclonal Antibody Market by Cancer Type (2018 and 2025)
- Monoclonal Antibody Market Distribution by Indication (2025)
- Cancer Tyrosine Kinase Inhibitor Market by Type and Target
- Development of the TKI Cancer Treatment Market (2010-2025)
- TKI Market by Cancer Indication (2018 and 2025)
- TKI Market Distribution by Cancer Indication (2018 and 2025)
- Extensive analysis of the monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) markets, focusing on type and target:
Regional Market Insights:
- Geographical Market Overviews:
- Thorough regional analysis including:
- United States and Canada
- Europe, Middle East, Africa (EMEA)
- Asia Pacific
- Latin America
- Targeted Cancer Therapeutics Market Summary by Region (2018-2025)
- Distribution by Therapy Type (Monoclonal antibodies, Tyrosine kinase inhibitors, Angiogenesis inhibitors, Proteasome inhibitors, CDK inhibitors, Other targeted therapies)
- Thorough regional analysis including:
Competitive Landscape:
- Market Share Analysis:
- Evaluation of key competitors and market share across major segments:
- Cancer Monoclonal Antibody Competitor Market Share (2018)
- Cancer TKI Competitor Market Share (2018)
- Cancer CDK Inhibitors Competitor Market Share (2018)
- Cancer Proteasome Inhibitor Competitor Market Share (2018)
- Evaluation of key competitors and market share across major segments:
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Cancer Monoclonal Antibody Market, by Target, 2018 and Forecast 2025 ($ millions)
| Target | 2018 Sales | 2025 Sales | CAGR 2018-2025 |
| PD-1 | $XX Million | $XX Million | XX% |
| HER2 | $XX Million | $XX Million | XX% |
| VEGF | $XX Million | $XX Million | XX% |
| CD20 | $XX Million | $XX Million | XX% |
| EGFR | $XX Million | $XX Million | XX% |
| CD38 | $XX Million | $XX Million | XX% |
| RANKL | $XX Million | $XX Million | XX% |
| CTLA-4 | $XX Million | $XX Million | XX% |
| PD-L1 | $XX Million | $XX Million | XX% |
| CD30 | $XX Million | $XX Million | XX% |
| PDGF | $XX Million | $XX Million | XX% |
Source: Kalorama Information
